Cardio-rheumatology: it’s time to collaborate
暂无分享,去创建一个
[1] I. Bruce,et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome , 2022, Annals of the Rheumatic Diseases.
[2] Deepak L. Bhatt,et al. Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis. , 2022, The New England journal of medicine.
[3] L. Fraenkel,et al. Barriers and facilitators for screening and treatment of hyperlipidemia among patients with inflammatory arthritis , 2020, BMC Rheumatology.
[4] J. Pope,et al. Appropriate cardiovascular disease risk assessment in systemic lupus erythematosus may be lacking in rheumatology practice. , 2018, Clinical and experimental rheumatology.
[5] James T. Elder,et al. Gaps in Diagnosis and Treatment of Cardiovascular Risk Factors in Patients with Psoriatic Disease: An International Multicenter Study , 2018, The Journal of Rheumatology.
[6] A. Ogdie,et al. Psoriasis and Psoriatic Arthritis Clinics Multicenter Advancement Network Consortium (PPACMAN) Survey: Benefits and Challenges of Combined Rheumatology-dermatology Clinics , 2017, The Journal of Rheumatology.
[7] J. Primdahl,et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016 update , 2016, Annals of the rheumatic diseases.
[8] D. Gladman,et al. Premature coronary heart disease in systemic lupus erythematosus: what risk factors do we understand? , 2013, Lupus.
[9] I. Holme,et al. Treatment to lipid targets in patients with inflammatory joint diseases in a preventive cardio-rheuma clinic , 2012, Annals of the rheumatic diseases.
[10] Maureen A. Smith,et al. Low frequency of primary lipid screening among medicare patients with rheumatoid arthritis. , 2011, Arthritis and rheumatism.